OncoPharm John Bossaer
-
- Ciência
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
-
Late April Updates
Lots of recent updates to cover this week...
1. Adjuvant pembrolizumab of RCC demonstrates OS improvement in NEJM publication (DOI: 10.1056/NEJMoa2312695)
2. Yet adjuvant nivolumab did not demonstrate OS improvement in the adjuvant setting. There may be a few reasons for this (https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA358)
3. A cytokine-fusion protein, nogapendekin alfa inbakicept, is approved for intravesicular use in BCG-unresponsive bladder cancer. This agent appears to activity in NSCLC too...
4. The Phase II APPLE trial provides some evidence than deferring osimertinib to the second-line setting in metastatic EGFR-mutated NSCLC may yield similar OS to first-line use of osimertinib. (https://doi.org/10.1200/JCO.23.01521)
5.The METALLICA study provides a nice roadmap for empiric metformin use when starting alpelisib (https://doi.org/10.1016/j.eclinm.2024.102520)
6. Does CPX-351 cause less intestinal damage than 7 + 3? And could that explain the discordance between time of neutropenia and infection rates? A mouse model suggests yes. (https://doi.org/10.1200/jco.2017.77.6112) -
-
HOPA '24, Site Agnositc T-DXd, & ALINA
What I learned (or relearned?) at HOPA's 2024 Annual Conference: updates in Neuro Oncology, fedratinib toxicity, and bispecific antibodies in multiple myeloma.
Also, fam-trastuzumab deruxtecan (T-DXd) garnered a site-agnostic approval for HER2 amplified solid tumors.
Finally, the ALINA study, adjuvant alectinib in ALK+ NSCLC, was published in this week's NEJM. -
Tumor Lysis Syndrome
Tumor Lysis Syndrome (TLS) is a foundational topic for all oncology clinicians. We discuss the what, the why, prevention, and treatment.
-
Updates In RCC, Pancreatic Cancer, And Skin Cancer In SOT
Discussing four papers that caught our eyes from the last few weeks:
Pazopanib vs. placebo following metastatectomy. Always concerning when placebo has an OS advantage.
ECOG-ACRIN E2810: https://doi.org/10.1200/JCO.23.01544
Gemcitabine vs. Gem + Paclitaxel (Taxol) in pancreatic cancer patients after FOLFIRINOX: https://doi.org/10.1200/JCO.23.00795
An RNA assay to predict gemcitabine sensitivity: https://doi.org/10.1200/JCO.22.02668
Management of skin cancers with ICIs in kidney transplant patients: https://doi.org/10.1200/JCO.23.02570 -
Colon Cancer Screening Wars
Two recent publications suggest more people may be choosing non-colonoscopy screening practices in the future. One is a new stool DNA test, while the other is a blood test.
How do they compare to the gold standard of colonoscopy?
Cell-free DNA blood test: DOI: 10.1056/NEJMoa2304714
Next generation stool DNA test: DOI: 10.1056/NEJMoa2310336